Edit

Fate Therapeutics

http://www.fatetherapeutics.com/

Last activity: 15.07.2025

Active

Categories: CarDevelopmentHealthTechInformationPlatformProduct

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Website visits

6.9K /mo.

Mentions

Location: United States, California, San Diego

Employees: 51-200

Founded date: 2007

Investors 2

Date	Name	Website
17.07.2021	ARCH Ventu...	archventur...
12.07.2023	Johns Hopk...	ventures.j...

Mentions in press and media 26

Date	Title	Description
15.07.2025	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company	BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their famili...
05.03.2024	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	-
28.02.2023	Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates	/EIN News/ -- Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initiated in FT576 Phase 1 Study for Multiple Myeloma; Interim Clinical Data from Single-dose Cohorts Showed Ob...
06.01.2023	Fate Stock Sinks. Analysts Downgrade Shares on End to Janssen Collaboration and Layoffs.	Fate Therapeutics was sinking Friday as analysts downgraded shares of the stem-cell company after it ended a collaboration agreement with Janssen Biotech and said it was reducing its work force. Fate (ticker: FATE) said in a press release t...
05.01.2023	Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives	/EIN News/ -- Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction Advancing Second-generation CD19-targeted CAR NK ...
05.01.2023	Fate Therapeutics plans mass layoffs, after early end to cell therapy deal with Janssen	SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies to treat autoimmune diseases and cancer, is now planning to cut back on both jobs and experimental drugs after an early end to a deal with Janss...
22.08.2021	Anti-aging research foundation sacks CSO Aubrey de Grey for disrupting sexual harassment probe	Caught in the center of a boiling controversy over accusations of sexual harassment leveled against their chief scientific officer, Aubrey de Grey, the board of directors of the SENS Research Foundation moved to fire ...
20.08.2021	Insilico finds a new partner for AI drug discovery; EU launches Illumina probe after Grail merger close	MIT star researcher and CRISPR pioneer Feng Zhang put a new paper out Thursday in Science detailing how a new technology could alter a field that’s already proven game-changing throughout the Covid-19 pandemic. Zhang and his team have devel...
19.08.2021	Fate's closely watched stem cell-derived NK program raises red flag over durability of response	At the cutting edge of oncology research, biotechs like Fate Therapeutics are looking for ways to craft next-gen cell therapies without relying on patients’ own cells. An early peek at the company’s clinical data looks ...
26.03.2021	Merck keeps it in the family as Robert Davis hands the CFO keys to Caroline Litchfield; Gilead loses Diana Brainard, with virology exec becoming CEO of AlloVir	Caroline Litchfield → With Robert Davis preparing to take over as Merck’s CEO, the Big Pharma stayed in-house to choose a successor in the job he won’t hold for much longer. Caroline Litchfield, who’s served at Merck since 1990 ...
13.02.2021	Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med	Late last summer, one of the earliest stem cell therapy companies got two government decisions in the span of three weeks: The USPTO granted them a patent for iPSC-derived CAR-T cells, and then the FDA cleared them for their first-in-human ...
10.07.2020	AstraZeneca signs computational drug discovery collaboration; J&J-partnered Fate cleared for the clinic	→ AstraZeneca has picked out its latest computational partner from Toronto, tapping ProteinQure to apply its structure-based design platform for the creation of peptide therapeutic libraries. The pharma giant is resp...
16.01.2019	Macular degeneration trial will be first human test in U.S. of Nobel-winning stem cell technique	Curing diabetes with stem cells? Everyone knew that would be hard. Parkinson’s disease? Harder. Alzheimer’s? Probably impossible. But age-related macular degeneration, a major cause of blindness? That was supposed to be low-hanging fruit. T...
27.01.2015	Live imaging captures how blood stem cells take root in the body	By Nancy Fliesler For years, the lab of Leonard Zon, MD, director of the Stem Cell Research Program at Boston Children’s Hospital, has sought ways to enhance bone marrow transplants for patients with cancer, serious immune deficiencies and ...
16.05.2013	With a band of biotech collaborators, RuiYi sets sail developing new biologic drugs for China	“There’s already an approved antibody that targets the receptor; ours targets the cytokine, so you can actually use a lot less,” Grayson said. “It’s a known biologic mechanism, and there’s a lot of data showing that it’s safe and it has the...
05.09.2012	Maker of stem cell modulators brings in $9.2 million for blood cancer trials	Location: San Diego, California. Solution/product: Fate develops stem cell modulators. Its lead drug, ProHema, uses a small molecule (FT1050) to modulate hematopoietic stem cells (HSC), or blood-forming cells, that are transplanted to resto...
23.08.2012	Stem cell biotech Fate nails down $9.2M	Fate Therapeutics has pieced together a $9.2 million round of equity financing, according to an SEC filing. Based on its knowledge of stem cell biology, the San Diego-based biotech has been nurturing a pipeline of experimental drugs that ai...
22.02.2011	Fate CEO Exits for New Co	Share Share on Facebook Share on Twitter LinkedIn Email Reprints Fate Therapeutics, the San Diego-based developer of stem cell therapies, said today that CEO Paul Grayson is leaving Fate to form a new company. The new company wasn’t named i...
15.10.2010	Exelixis Gets $60M from Bristol, Genentech Surpasses Original Herceptin, Synosia Pockets $30M, & More Bay Area Life Sciences News	Share Share on Facebook Share on Twitter LinkedIn Email Reprints News on cancer drugs, stem cells, and the rare item about promising drugs for Parkinson’s disease crossed our desk this week. —South San Francisco-based Exelixis (NASDAQ: EXEL...
16.11.2009	Fate Therapeutics completed $30M Series B Financing	Fate Therapeutics, Inc., a La Jolla, CA-based developer of a Stem Cell Modulator, FT1050, to enhance hematopoietic stem cell (HSC) proliferation and homing, has completed a $30m Series B financing. The round was led by OVP Venture Partners ...
16.11.2009	Fate Therapeutics Raises $30M	La Jolla-based Fate Therapeutics is reporting this morning that it has raised $30M in a Series B financing round. The firm, which develops stem cell therapies, said the funding was led by OVP Venture Partners, and included Astellas Venture ...
11.04.2008	Twist of Fate—How A Band of VCs Recruited a Scientific Dream Team to Control Our Cells’ Destinies	Share Share on Facebook Share on Twitter LinkedIn Email Reprints “Like all VCs,” Amir Nashat is saying, “we come late to the story.” Nashat is talking about the formation of Fate Therapeutics, and in one sense what he’s saying is true. Vent...
20.12.2007	Harvard’s Brock Reeve Sizes up the Prospects for Stem Cells in 2008 and Beyond	Share Share on Facebook Share on Twitter LinkedIn Email Reprints 2007 has been an outstanding year for stem cells—those much-ballyhooed cells with the ability to develop into numerous tissues in the body and ultimately, researchers hope, re...
30.11.2007	Life sciences briefing: Friday, Nov. 30, 2007	Featured companies: Fate Therapeutics, Medgenics, Satoris UPDATED: Expanded items on Fate Therapeutics and Medgenics. The Satoris item is now a standalone post here. Fate Therapeutics launches regenerative-medicine quest with $12M — In one ...
-	Maker of stem cell modulators brings in $9.2 million for blood cancer trials	Company name: Fate Therapeutics. Industry: regenerative medicine. Location: San Diego, California. Solution/product: Fate develops stem cell modulators. Its lead drug, ProHema, uses a small molecule (FT1050) to modulate hematopoietic stem c...
-	With a band of biotech collaborators, RuiYi sets sail developing new biologic drugs for China	The La Jolla, California, biotech formerly known as Anaphore is looking a little different these days. Under the leadership of former Fate Therapeutics CEO Paul Grayson, Anaphore changed its name to RuiYi Inc., honed its focus from developi...

Fate Therapeutics

Investors 2

Mentions in press and media 26

Reviews 0